Valuation: Amgen Inc.

Market Cap 229B 202B 191B 173B 325B 21,977B 328B 2,294B 884B 11,223B 860B 841B 36,115B P/E 2026 *
26.8x
P/E 2027 * 24x
Enterprise Value 271B 239B 226B 205B 384B 25,958B 388B 2,710B 1,044B 13,255B 1,016B 994B 42,656B EV / Sales 2026 *
6.95x
EV / Sales 2027 * 6.57x
Free-Float
99.77%
Yield 2026 *
2.38%
Yield 2027 * 2.52%
1 day+1.26%
1 week+4.45%
Current month+0.59%
1 month+0.59%
3 months+18.60%
6 months+21.98%
Current year+33.05%
1 week 355
Extreme 355
376.75
1 month 325.5
Extreme 325.5
383.05
Current year 271.8
Extreme 271.8
383.05
1 year 239.2
Extreme 239.2
383.05
3 years 230
Extreme 230
383.05
5 years 174.58
Extreme 174.58
383.05
10 years 120.65
Extreme 120.65
383.05
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%+4.45% - - 229B
-0.01%+1.24%+63.06%+120.55% 1,056B
-1.61%-0.60%+47.32%+71.79% 645B
-1.12%-0.72%+17.98%+76.63% 465B
+0.40%-1.08%+89.97%+45.00% 368B
+0.31%-3.58%+34.74%+41.18% 335B
+0.05%+2.93%+20.89%+29.63% 275B
-0.85%-0.90%+10.16%+12.49% 255B
+1.32%+3.27%+54.63%+57.63% 229B
-0.61%-0.91%+34.33%+101.87% 188B
Average +0.18%+0.12%+41.45%+61.86% 423.98B
Weighted average by Cap. +0.17%+0.30%+46.53%+74.23%

Financials

2026 *2027 *
Net sales 38.94B 34.36B 32.51B 29.49B 55.28B 3,736B 55.83B 390B 150B 1,908B 146B 143B 6,140B 40.31B 35.57B 33.66B 30.52B 57.23B 3,868B 57.79B 404B 156B 1,975B 151B 148B 6,356B
Net income 8.58B 7.57B 7.16B 6.5B 12.18B 823B 12.3B 85.95B 33.13B 420B 32.22B 31.52B 1,353B 9.39B 8.29B 7.84B 7.11B 13.33B 901B 13.47B 94.09B 36.26B 460B 35.27B 34.5B 1,481B
Net Debt 41.49B 36.61B 34.64B 31.41B 58.9B 3,981B 59.48B 416B 160B 2,033B 156B 152B 6,542B 35.82B 31.61B 29.91B 27.12B 50.85B 3,437B 51.35B 359B 138B 1,755B 134B 132B 5,648B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
30/09/26 EUR 372.95 +1.39% 54
29/09/26 EUR 367.85 +0.73% 393
28/09/26 EUR 365.20 +1.71% 704
25/09/26 EUR 359.05 +0.87% 111
24/09/26 EUR 355.95 -0.31% 364
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
423.64USD
Average target price
390.94USD
Spread / Average Target
-7.72%

Quarterly revenue - Rate of surprise